Info
bc_N0
- for HR(+)HER2(-):
- consider check gene expression assay
- if low risk, and T1a:
- no chemotherapy
- adjuvant endocrine therapy per menopause status
- else: CAF
- for HR(-), T1b to T2
- TNBC: AC followed by T
- refer to radiation oncologist for further evaluation
- radiation therapy is indicated if breast conservation surgery
- No OS for RT after BCS for pts >70 yo, ER+, & node (−) (CALGB 9343, JCO 2013;31:2382)
Explain
- aims: decrease recurrence risk, and improve survival
- recurrence: TNBC, HER2+ mostly in first 3-5 years. ER+ steady risk 0-14 years